Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

R F Schlenk; P Frech; D Weber; P Brossart; H-A Horst; D Kraemer; G Held; M Ringhoffer; A Burchardt; G Kobbe; K Götze; D Nachbaur; T Fischer; M Lübbert; H R Salih; H Salwender; G Wulf; E Koller; M Wattad; W Fiedler; S Kremers; H Kirchen; B Hertenstein; P Paschka; V I Gaidzik; V Teleanu; M Heuser; F Thol; K Döhner; J Krauter; A Ganser; H Döhner; the German-Austrian AMLSG

doi:10.1038/leu.2017.22

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

Leukemia. 2017 May;31(5):1217-1220. doi: 10.1038/leu.2017.22. Epub 2017 Jan 18.

Authors

R F Schlenk^{1

2}, P Frech¹, D Weber¹, P Brossart³, H-A Horst⁴, D Kraemer⁵, G Held⁶, M Ringhoffer⁷, A Burchardt⁸, G Kobbe⁹, K Götze¹⁰, D Nachbaur¹¹, T Fischer¹², M Lübbert¹³, H R Salih¹⁴, H Salwender¹⁵, G Wulf¹⁶, E Koller¹⁷, M Wattad¹⁸, W Fiedler¹⁹, S Kremers²⁰, H Kirchen²¹, B Hertenstein²², P Paschka¹, V I Gaidzik¹, V Teleanu¹, M Heuser²³, F Thol²³, K Döhner¹, J Krauter²³, A Ganser²³, H Döhner¹; the German-Austrian AMLSG

Affiliations

¹ Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
² NCT Trial Center, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
³ Department of Internal Medicine III, University Hospital of Bonn, Bonn, Germany.
⁴ Department of Internal Medicine II, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany.
⁵ Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany.
⁶ Department of Internal Medicine I, University Hospital of Saarland, Homburg, Germany.
⁷ Department of Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
⁸ Department of Hematology/Oncology, University-hospital Giessen, Giessen, Germany.
⁹ Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
¹⁰ Department of Internal Medicine III, Technical University of Munich, Munich, Germany.
¹¹ Department of Internal Medicine V, University Hospital Innsbruck, Innsbruck, Austria.
¹² Department of Medicine III, Johannes Gutenberg-University Mainz, Mainz, Germany.
¹³ Department of Hematology and Oncology, University Hospital of Freiburg, Freiburg, Germany.
¹⁴ Department of Hematology and Oncology, Eberhard-Karls University, Tübingen, Germany.
¹⁵ Department of Hematology/Oncology, Asklepios Klinik Altona, Hamburg, Germany.
¹⁶ Department of Hematology and Oncology, University Hospital of Göttingen, Göttingen, Germany.
¹⁷ Department of Hematology/Oncology, Hanuschkrankenhaus, Wien, Austria.
¹⁸ Department of Hematology Oncology, Kliniken Essen-Süd, Essen, Germany.
¹⁹ Department of Internal Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
²⁰ Department of Hematology/Oncology, Caritas-Krankenhaus, Lebach, Germany.
²¹ Department of Hematology/Oncology, Krankenhaus der Barmherzigen Brüder, Trier, Germany.
²² Department of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany.
²³ Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

No abstract available

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Prognosis
Recurrence
Salvage Therapy*
Treatment Outcome
Young Adult